文献速递呼吸危重症与机械通气呼吸道感染

免疫功能低下患者急性呼吸衰竭支气管镜检查的诊断与结局

Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy.
PubMed 文献 · Eur Respir J · 2019-07-25

该研究为Efraim前瞻性 multinational 观察性研究的预先计划二次分析,纳入1611例ICU免疫功能低下急性呼吸衰竭患者,比较仅无创检测与加做支气管镜者的结局。支气管镜诊断调整产出27%、治疗调整产出38%,但与更高ICU死亡率(40% vs 28%)和住院死亡率(49% vs 41%)相关,倾向评分匹配后住院死亡风险仍升高(OR 1.41,95%CI 1.08-1.81)。

要点

  • 支气管镜诊断调整产出27%,治疗调整产出38%。
  • 支气管镜与更高ICU死亡率(40% vs 28%)和住院死亡率(49% vs 41%)相关。
  • 匹配后支气管镜仍与住院死亡风险升高相关(OR 1.41,95%CI 1.08-1.81)。

核心结论

  • 支气管镜与诊断改善和管理改变相关,但也与住院死亡率升高相关。
  • 个体化病例中风险与获益的平衡有待进一步研究。

研究设计与样本

  • Efraim研究的预先计划二次分析,为前瞻性、跨国、观察性研究。
  • 纳入1611例入住ICU的免疫功能低下急性呼吸衰竭患者。
  • 比较仅无创检测者与加做支气管镜者,采用双变量分析和倾向评分匹配。

主要发现

  • 618例(39%)患者接受了支气管镜,这些患者更可能为血液系统恶性肿瘤且病情严重度评分更高。
  • 支气管镜单独在165例患者中实现诊断(调整诊断产出27%)。
  • 支气管镜导致236例患者(38%)管理改变(治疗产出)。
  • 支气管镜与呼吸状态恶化相关者69例(11%)。
  • 支气管镜与更高ICU死亡率(40% vs 28%;p<0.0001)和住院死亡率(49% vs 41%;p=0.003)相关,匹配后住院死亡风险仍升高(OR 1.41,95%CI 1.08-1.81)。

临床怎么用

  • 在免疫功能低下急性呼吸衰竭患者中,支气管镜可提高诊断并改变管理,但需权衡住院死亡风险升高。
  • 应个体化评估支气管镜的风险与获益。

局限性

  • 为观察性研究的二次分析,可能存在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We wished to explore the use, diagnostic capability and outcomes of bronchoscopy added to noninvasive testing in immunocompromised patients. In this setting, an inability to identify the cause of acute hypoxaemic respiratory failure is associated with worse outcome. Every effort should be made to obtain a diagnosis, either with noninvasive testing alone or combined with bronchoscopy. However, our understanding of the risks and benefits of bronchoscopy remains uncertain. PATIENTS AND METHODS: This was a pre-planned secondary analysis of Efraim, a prospective, multinational, observational study of 1611 immunocompromised patients with acute respiratory failure admitted to the intensive care unit (ICU). We compared patients with noninvasive testing only to those who had also received bronchoscopy by bivariate analysis and after propensity score matching. RESULTS: Bronchoscopy was performed in 618 (39%) patients who were more likely to have haematological malignancy and a higher severity of illness score. Bronchoscopy alone achieved a diagnosis in 165 patients (27% adjusted diagnostic yield). Bronchoscopy resulted in a management change in 236 patients (38% therapeutic yield). Bronchoscopy was associated with worsening of respiratory status in 69 (11%) patients. Bronchoscopy was associated with higher ICU (40% versus 28%; p<0.0001) and hospital mortality (49% versus 41%; p=0.003). The overall rate of undiagnosed causes was 13%. After propensity score matching, bronchoscopy remained associated with increased risk of hospital mortality (OR 1.41, 95% CI 1.08-1.81). CONCLUSIONS: Bronchoscopy was associated with improved diagnosis and changes in management, but also increased hospital mortality. Balancing risk and benefit in individualised cases should be investigated further.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Bauer PR, Chevret S, Yadav H, et al. Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy. Eur Respir J. 2019. PMID: 31109985. doi:10.1183/13993003.02442-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。